ArticleMalaria journal2012
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium.
Article in Malaria journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Systematic analysis of direct antiglobulin test results in post-artesunate delayed haemolysis.Malaria journal · 2021Pooled it
- Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.BMC infectious diseases · 2016Trial
- Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial.PLoS medicine · 2016Trial
- Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.BMC infectious diseases · 2015Trial
- Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.Malaria journal · 2014Trial
- Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study.Malaria journal · 2012Trial
- Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study.Clinical pharmacokinetics · 2025Article
- Use of artesunate in the treatment of severe imported malaria in France: review of the effectiveness and real-life safety in two French university hospitals.BMC infectious diseases · 2023Observational
- Rhino-orbital mucormycosis in a patient with no susceptibility following P.vivax malaria infection-a case report.BMC ophthalmology · 2022Article
- Article
- Treatment for Severe Malaria: Post-Artesunate Delayed Haemolysis and Neutropenia.Healthcare (Basel, Switzerland) · 2022Article
- The sting in the tail of severe falciparum malaria: Post-artesunate delayed haemolysis.Southern African journal of infectious diseases · 2022Article
- The Role of Nonapoptotic Programmed Cell Death - Ferroptosis, Necroptosis, and Pyroptosis - in Pancreatic Ductal Adenocarcinoma Treatment.Frontiers in oncology · 2022Review
- Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States-April 2019 Through December 2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Case Report: Autoimmune Hemolysis Anemia After Dihydroartemisinin and Piperaquine for UncomplicatedFrontiers in medicine · 2021Article
- Changes in the clinical presentation and outcomes of patients treated for severe malaria in a referral French university intensive care unit from 2004 to 2017.Annals of intensive care · 2020Article
- Delayed haemolysis after treatment with intravenous artesunate in patients with severe malaria in India.Malaria journal · 2020Observational
- Positive direct antiglobulin test in post-artesunate delayed haemolysis: more than a coincidence?Malaria journal · 2019Article
- Artesunate-Induced Severe Autoimmune Hemolytic Anemia in Complicated Malaria.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2018Article
- Development of Delayed Hemolytic Anemia After Treatment with Oral Artemether-Lumefantrine in Two Patients with Severe Falciparum Malaria.The American journal of tropical medicine and hygiene · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately, artesunate became available in the Netherlands and Belgium through a named patient programme. This is the largest case series of artesunate treated patients with severe malaria in Europe.
methodsHospitalized patients treated with IV artesunate between November 2007 and December 2010 in the Netherlands and Belgium were retrospectively evaluated. Patient characteristics, treatment and clinical outcome were recorded on a standardized form and mortality, parasite clearance times and the occurrence of adverse events were evaluated.
resultsOf the 68 treated patients, including 55 with severe malaria, two patients died (2/55 = 3.6%). The mean time to 50% parasite clearance (PCT50), 90% and 99% were 4.4 hours (3.9 - 5.2), 14.8 hours (13.0 - 17.2), and 29.5 hours (25.9 - 34.4) respectively. Artesunate was well tolerated. However, an unusual form of haemolytic anaemia was observed in seven patients. The relationship with artesunate remains uncertain.
conclusionsData from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity. However, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment.Treatment of IV artesunate should be limited to the period that IV treatment is required and should be followed by a full oral course of an appropriate anti-malarial drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.